Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment
Clicks: 276
ID: 115788
2000
None of the registries has provided a risk estimate exceeding that expected in the disorder treated, and no pattern of defects has been observed. Whereas information from the larger registries is reassuring regarding risk, these studies cannot rule out possible small excess risks from use of these d …
| Reference Key |
r2000americanmonitoring
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Reiff-Eldridge R;Heffner CR;Ephross SA;Tennis PS;White AD;Andrews EB;; |
| Journal | american journal of obstetrics and gynecology |
| Year | 2000 |
| DOI | DOI not found |
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
pregnancy
female
Prospective Studies
risk factors
pregnancy complications
abnormalities
pregnancy outcome*
antiviral agents / adverse effects
pregnancy trimester
pmid:10649172
doi:10.1016/s0002-9378(00)70506-0
r reiff-eldridge
c r heffner
e b andrews
drug-induced / epidemiology*
acyclovir / adverse effects
anticonvulsants / adverse effects
drug industry*
epilepsy / drug therapy
lamotrigine
first
registries
sumatriptan / adverse effects
triazines / adverse effects
vasoconstrictor agents / adverse effects
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.